MicroRNA Expression Profiling in HCV-Infected Human Hepatoma Cells Identifies Potential Anti-Viral Targets Induced by Interferon-α

Objective Increasing evidence suggests that miRNAs have a profound impact on host defense to Hepatitis C virus (HCV) infection and clinical outcome of standard HCV therapy. In this study, we investigated modulation of miRNA expression in Huh7.5 hepatoma cells by HCV infection and in vitro interferon-αtreatment. Methods MiRNA expression profiling was determined using Human miRNA TaqMan® Arrays followed by rigorous pairwise statistical analysis. MiRNA inhibitors assessed the functional effects of miRNAs on HCV replication. Computational analysis predicted anti-correlated mRNA targets and their involvement in host cellular pathways. Quantitative RTPCR confirmed the expression of predicted miRNA-mRNA correlated pairs in HCV-infected Huh7.5 cells with and without interferon-α. Results Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-α treatment (p<0.01). The miR-30(a-d) cluster and miR-130a/301 and their putative mRNA targets were predicted to be associated with cellular pathways that involve Hepatitis C virus entry, propagation and host response to viral infection. Conclusions HCV differentially modulates miRNAs to facilitate entry and early establishment of infection in vitro. Interferon-α appears to neutralize the effect of HCV replication on miRNA regulation thus providing a potential mechanism of action in eradicating HCV from hepatocytes.

[1]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[2]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[3]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[4]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[5]  Stefano Volinia,et al.  Interferon modulation of cellular microRNAs as an antiviral mechanism , 2007, Nature.

[6]  D. Seol,et al.  Co‐expression and regulation of Met and Ron proto‐oncogenes in human hepatocellular carcinoma tissues and cell lines , 1997, Hepatology.

[7]  F. Stickel,et al.  Role of integrins in fibrosing liver diseases. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[8]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[9]  G. Szabo,et al.  Emerging role of microRNAs in liver diseases. , 2009, World journal of gastroenterology.

[10]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[11]  David Liu,et al.  DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis , 2007, BMC Bioinformatics.

[12]  K. Gunsalus,et al.  Combinatorial microRNA target predictions , 2005, Nature Genetics.

[13]  D. Bartel,et al.  Weak Seed-Pairing Stability and High Target-Site Abundance Decrease the Proficiency of lsy-6 and Other miRNAs , 2011, Nature Structural &Molecular Biology.

[14]  R. Sun,et al.  NKG2D–retinoic acid early inducible‐1 recognition between natural killer cells and kupffer cells in a novel murine natural killer cell–dependent fulminant hepatitis , 2009, Hepatology.

[15]  R. Ray,et al.  Hepatitis C Virus Infection Modulates Expression of Interferon Stimulatory Gene IFITM1 by Upregulating miR-130A , 2012, Journal of Virology.

[16]  M. Buti,et al.  Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. , 2006, Journal of hepatology.

[17]  J. Fujimoto,et al.  Expression of hepatocyte growth factor and its receptor c‐met proto‐oncogene in hepatocellular carcinoma , 1997, Hepatology.

[18]  D. Huang,et al.  Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. , 2006, The Journal of infectious diseases.

[19]  Georgios Papachristoudis,et al.  Human microRNA target analysis and gene ontology clustering by GOmir, a novel stand-alone application , 2009, BMC Bioinformatics.

[20]  H. Cai,et al.  Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. , 2002, Gastroenterology.

[21]  C. Scagnolari,et al.  Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha , 2010, Virology Journal.

[22]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[23]  K. Shimotohno,et al.  Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C , 2010, BMC Medical Genomics.

[24]  Anton J. Enright,et al.  Human MicroRNA Targets , 2004, PLoS biology.

[25]  H. Cai,et al.  Interferon-α activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes , 2002 .

[26]  S. Cohen,et al.  microRNA functions. , 2007, Annual review of cell and developmental biology.

[27]  P. Sarnow,et al.  Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA , 2005, Science.

[28]  A. Yoshimura,et al.  SOCS, Inflammation, and Autoimmunity , 2011, Front. Immun..

[29]  A. Sönnerborg,et al.  A cell-binding Arg-Gly-Asp sequence is present in close proximity to the major linear antigenic region of HCV NS3. , 1994, Biochemical and biophysical research communications.

[30]  E. Majda-Stanisławska,et al.  Expression of microRNA-155 precursor in peripheral blood mononuclear cells from Hepatitis C patients after antiviral treatment. , 2010, Acta virologica.

[31]  Takaya Saito,et al.  MicroRNAs--targeting and target prediction. , 2010, New biotechnology.

[32]  W. Filipowicz,et al.  Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy , 2009, Nature Medicine.

[33]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.

[34]  Limin Chen,et al.  ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. , 2010, The Journal of general virology.

[35]  Charles M. Rice,et al.  Unravelling hepatitis C virus replication from genome to function , 2005, Nature.

[36]  B. Cullen,et al.  Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. , 2008, Cell host & microbe.

[37]  Yang Wang,et al.  MicroRNA: past and present. , 2007, Frontiers in bioscience : a journal and virtual library.

[38]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.